Cough Desensitization Therapy: Pilot 2

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

May 30, 2022

Study Completion Date

August 30, 2022

Conditions
Cough
Interventions
BIOLOGICAL

Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer

Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through a dosimeter-controlled nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. Individual doses will never exceed 1000 micromolar. Cumulative doses per session will never exceed 2000 micromolar. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.

BIOLOGICAL

Saline

Participants will be repeatedly exposed to a saline through a dosimeter-controlled nebulizer during treatment sessions. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session.

Trial Locations (1)

59812

University of Montana, Missoula

All Listed Sponsors
lead

University of Montana

OTHER